Renibus Therapeutics Announces $47 Million Financing to Advance Lead Program RBT-1 Through Pivotal Phase 3 Trial
- Tuesday, July 18, 2023, 7:02
- Finance
- Add a comment
-Financing follows positive final Phase 2 results of RBT-1 presented at AATS 2023- -Proceeds fund pivotal Phase 3 trial of RBT-1; on track to initiate in Q3 2023- SOUTHLAKE, Texas, July 18, 2023 /PRNewswire/ — Renibus Therapeutics, Inc., (“Renibus”), a clinical-stage biopharmaceutical…
About the Author
adminasapcorp has written 41538 stories on this site.